Le­vo Ther­a­peu­tics miss­es pri­ma­ry end­point in PhI­II tri­al of Prad­er-Willi drug — the lat­est set­back in a dis­as­ter-prone field

Mark­ing yet an­oth­er set­back in the Prad­er-Willi Syn­drome field, Le­vo Ther­a­peu­tics failed to hit its pri­ma­ry end­point in a Phase III study of in­tranasal car­be­tocin …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER